GO
Loading...

Sales

More

  • Macy's Falls in Pre-Market     Wednesday, 9 May 2012 | 9:21 AM ET

    Macy's reported Q1 profits at $0.43 per share versus a $0.40 estimate, but guidance is below Wall Street forecasts. Charles Grom, Deutsche Bank senior analyst and Liz Dunn, Macquarie Group analyst, share perspective.

  • Telsey CEO on Retail Winners & Losers     Thursday, 3 May 2012 | 12:09 PM ET

    Dana Telsey, Telsey Advisory Group CEO, offers insight on earnings from the retail industry.

  • Whole Foods' Organic Growth     Thursday, 3 May 2012 | 9:48 AM ET

    Whole Foods profit topped Wall Street's expectations, ringing up earnings of 64 cents per share. Charles Grom, senior analyst at Deutsche Bank, weighs in.

  • Clorox CEO on Commodity Inflation     Wednesday, 2 May 2012 | 4:33 PM ET

    Donald Knauss, Clorox chairman and CEO discusses his company's strategies to save on costs and improve margins.

  • Are Men 'Out-Shopping' Women?     Wednesday, 2 May 2012 | 2:47 PM ET

    According to iProspect, 70% of affluent men prefer to research and buy online, reports CNBC's Courtney Reagan.

  • Amazon.com Pulling DMAA Products     Tuesday, 1 May 2012 | 2:56 PM ET

    CNBC's Darren Rovell reports Amazon.com is pulling all products containing DMAA, an ingredient the FDA stated does not derive from a plant.

  • CNBC's Darren Rovell reports on beverage stocks, including shares of Monster Beverage Corporation moving higher on an alleged acquisition by Coca-Cola.

  • Home Ownership Declines     Monday, 30 Apr 2012 | 1:10 PM ET

    Home ownership is falling to 65.4% from 66.4% one year ago, reports CNBC's Diana Olick.

  • Johnson & Johnson CEO Takes the Reigns     Thursday, 26 Apr 2012 | 4:40 PM ET

    Alex Gorsky, Johnson & Johnson CEO discusses the near and long term innovative goals his company has in order to develop global growth.

  • Ahead of Netflix's Earnings     Monday, 23 Apr 2012 | 12:41 PM ET

    Silver has reached a 13-week low and the FMHR traders discuss the key catalysts. Netflix is also set to announce its Q1 earnings data after today's closing bell, with Michael Pachter, Wedbush Securities analyst.

  • Ron Paul on Presidential Politics     Monday, 23 Apr 2012 | 8:40 AM ET

    Republican presidential candidate, Rep. Ron Paul discusses fixing the U.S. economy, fighting the Fed, Iran and foreign policy, and his plan to restore America.

  • Paying More for Pork     Thursday, 19 Apr 2012 | 2:56 PM ET

    The U.S. supermarket bacon business is worth $2.5 billion and new pig welfare laws in the EU could push bacon prices up 20% in the UK, reports CNBC's Darren Rovell.

  • Time to Get Bullish on McDonald's?     Thursday, 19 Apr 2012 | 1:51 PM ET

    A preview of McDonald's earnings report and March's same-store sales, both out tomorrow, with Nicole Miller Regan, Piper Jaffray analyst and CNBC's Phil LeBeau.

  • Tumi Surges in Debut     Thursday, 19 Apr 2012 | 10:45 AM ET

    Dana Telsey, Telsey Advisory Group CEO, discusses the outlook for Tumi and the entire luxury sector.

  • Threats to Recovery?     Thursday, 19 Apr 2012 | 10:09 AM ET

    Discussing Thursday morning's major economic reports, including jobless claims and existing home sales, with Mark Zandi, Moody's Analytics chief economist.

  • Existing Home Sales Down 2.6%     Thursday, 19 Apr 2012 | 10:05 AM ET

    Big drops in inventories in the South and West are pushing home sales down, explains CNBC's Diana Olick.

  • Market Confidence Revival     Monday, 16 Apr 2012 | 2:13 PM ET

    Discussing whether the old saying, "sell in May and go away" applies to the current market, with Jim Paulsen, Wells Capital Management.

  • Could growth in the home improvement industry outpace GDP in the future? Peter Keith, Piper Jaffray analyst, explains why he's upgrading shares of Home Depot and Lowe's.

  • Doug Kass, Seabreeze Partners founder & president, explains why he sees a multi-year recovery in the U.S. housing market.

  • Sanofi CEO on Profit Pipeline     Thursday, 12 Apr 2012 | 4:35 PM ET

    Sanofi CEO Christopher Viehbacher discusses his company's $20 billion acquisition of Genzyme and other opportunities he sees in the pharmaceutical market.